Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity.

Evelo Biosciences Inc. (NASDAQ:EVLO) has gained 44% to $7.54 since reporting the results Wednesday for lead program EDP1815 in mild-to-moderate atopic dermatitis. It’s the second indication in which Evelo has reported clinical efficacy for the program after psoriasis...